Tumor necrosis factor-a antagonist-induced psoriasis: Yet another paradox in medicine

Clinical Rheumatology

Volumn 27, Issue 3, 2008, Pages 377-380

  Aslanidis, Spyros ^a   Pyrpasopoulou, Athina ^a   Douma, Stella ^a   Triantafyllou, Areti ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

Induction; Pathophysiological mechanisms; Psoriatic lesions; TNFa antagonists

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CYCLOSPORIN A; INFLIXIMAB; TOPICAL AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MALE; PALMAR PUSTULOSIS; PATHOPHYSIOLOGY; PHENOMENOLOGY; PLAGUE PSORIASIS; PLANTAR PUSTULOSIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS GUTTATA; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG ANTAGONISM; IMMUNOLOGY; MIDDLE AGED; RHEUMATIC DISEASE;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PSORIASIS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41949136361     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0789-5     Document Type: Article

References (30)

1. JM Dayer 2002 The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis Jt Bone Spine 69 123 132 10.1016/S1297-319X(02)00363-9 (Pubitemid 34450353)
2. PJ Mease CE Antoni 2005 Psoriatic arthritis treatment: biological response modifiers Ann Rheum Dis 64 Suppl II ii78 ii82 15708944 10.1136/ard.2004.034157 1:CAS:528:DC%2BD2MXisVOrtbo%3D (Pubitemid 40288529)
3. T Bongartz AJ Sutton MJ Sweeting, et al. 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275 2285 16705109 10.1001/jama.295.19.2275 1:CAS:528:DC%2BD28Xksl2ktrk%3D (Pubitemid 43736578)
4. JD Cohen I Bournerias V Buffard, et al. 2007 Psoriasis induced by tumor necrosis factor-α antagonist therapy: a case series J Rheumatol 34 380 385 17013997 1:CAS:528:DC%2BD2sXjtFCntr0%3D
5. M Flendrie W Vissers M Creemers, et al. 2005 Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study Arthritis Res Ther 7 R666 R676 15899052 10.1186/ar1724 1:CAS:528:DC%2BD2MXkt1Cjsr8%3D
6. PP Sfikakis A Iliopoulos A Elezoglou, et al. 2005 Psoriasis induced by anti-tumor necrosis factor therapy Arthritis Rheum 52 2513 2518 16052599 10.1002/art.21233 1:STN:280:DC%2BD2MvhsV2rsQ%3D%3D (Pubitemid 41117439)
7. G Michaelsson U Kajermo A Michaelsson, et al. 2005 Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-α in the normal plantar eccrine sweat duct? Br J Dermatol 153 1243 1244 16307676 10.1111/j.1365-2133.2005.06977.x 1:STN:280:DC%2BD2MnislSlsA%3D%3D (Pubitemid 41779595)
8. HJ Bovenschen PC Van De Kerkhof WJ Gerritsen, et al. 2005 The role of lesional T cells in recalcitrant psoriasis during infliximab therapy Eur J Dermatol 15 454 458 16280298 1:STN:280:DC%2BD2MngtV2rtg%3D%3D
9. S Kary M Worm H Audring, et al. 2006 New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving TNF-α antagonists Ann Rheum Dis 65 405 407 16150791 10.1136/ard.2005. 037424 1:STN:280:DC%2BD287hvFequw%3D%3D (Pubitemid 43268235)
10. D Pirard D Arco V Debrouckere, et al. 2006 Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview Dermatology 213 182 186 17033165 10.1159/000095033 1:CAS:528:DC%2BD28XhtVKjtb3F (Pubitemid 44567826)
11. S Aslanidis A Pyrpasopoulou M Leontsini, et al. 2006 Anti-TNF-alpha- induced psoriasis: case report of an unusual adverse event Int J Dermatol 45 982 983 16911391 10.1111/j.1365-4632.2006.03041.x (Pubitemid 44145038)
12. I Sari S Akar M Birlik, et al. 2006 Anti-tumor necrosis factor-alpha-induced psoriasis J Rheumatol 33 1411 1414 16821276
13. CH Roux O Brocq N Leccia, et al. 2007 New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol 34 434 437 17295430
14. AB Gottlieb RT Matheson N Lowe, et al. 2003 A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 1627 1632 14676082 10.1001/archderm.139.12.1627 1:CAS:528:DC%2BD2cXivVamuw%3D%3D (Pubitemid 37523083)
15. PJ Mease BS Goffe J Metz, et al. 2000 Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial Lancet 356 385 390 10972371 10.1016/S0140-6736(00)02530-7 1:CAS:528:DC%2BD3cXls1Cksr8%3D
16. PJ Mease CE Antoni DD Gladman, et al. 2005 Psoriatic arthritis assessment tools in clinical trials Ann Rheum Dis 64 Suppl II ii49 ii54 15708937 10.1136/ard.2004.034165 (Pubitemid 40288522)
17. C Antoni A Kavanaugh B Kirkham, et al. 2005 The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy Arthritis Rheum 52 1227 1236 15818699 10.1002/art.20967 1:CAS:528:DC%2BD2MXktFCktbw%3D Erratum in Arthritis Rheum 52:2951 (Pubitemid 40530131)
18. C Antoni A Kavanaugh B Kirkham, et al. 2003 The one year results of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy Arthritis Rheum 48 S265
19. DD Gladman PJ Mease MA Cifaldi, et al. 2007 Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: Patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) Ann Rheum Dis 66 163 168 17046964 10.1136/ard.2006.057901 1:CAS:528:DC%2BD2sXislChs7o%3D (Pubitemid 46226048)
20. MP Schon WH Boehncke 2005 Psoriasis N Engl J Med 352 1899 1912 15872205 10.1056/NEJMra041320 1:CAS:528:DC%2BD2MXjvVegsLY%3D (Pubitemid 40627816)
21. CEM Griffiths JJ Voorhees BJ Nickoloff 1989 Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor J Am Acad Dermatol 20 617 629 2497153 1:STN:280:BiaB3svntFY%3D
22. JNWN Barker V Sarma RS Mitra, et al. 1990 Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors J Clin Invest 85 605 608 2105343 1:CAS:528:DyaK3cXhtlOhs7g%3D 10.1172/JCI114481
23. M Detmar LF Brown KP Claffey, et al. 1994 Overexpression of vascular permeability factor/ vascular endothelial growth factor and its receptors in psoriasis J Exp Med 180 1141 1146 8064230 10.1084/jem.180.3.1141 1:CAS:528:DyaK2cXlsFCksbw%3D (Pubitemid 24256627)
24. K Kuroda A Sapadin T Shoji, et al. 2001 Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis J Invest Dermatol 116 713 720 11348459 10.1046/j.1523-1747.2001.01316.x 1:CAS:528:DC%2BD3MXktVanuro%3D (Pubitemid 32467649)
25. P-P Tak M Kraan A Goedkoop, et al. 2003 Early effects of infliximab therapy on inflammatory cells in lesional epidermis and synovial tissue of patients with psoriatic arthritis Arthritis Rheum 48 S168
26. P-P Tak M Kraan A Goedkoop, et al. 2003 Infliximab reduces the expression of adhesion molecules in skin and synovial tissue of patients with psoriatic arthritis Arthritis Rheum 48 S266 10.1002/art.10700 (Pubitemid 36091672)
27. S Benoit A Toksoy EB Brocker, et al. 2004 Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression Br J Dermatol 150 1009 1012 15149518 10.1111/j.1365-2133.2004.05960.x 1:STN:280:DC%2BD2c3ltFWnsQ%3D%3D (Pubitemid 38903538)
28. J Banchereau V Pascual AK Palucka 2004 Autoimmunity through cytokine-induced dendritic cell activation Immunity 20 539 550 15142523 10.1016/S1074-7613(04)00108-6 1:CAS:528:DC%2BD2cXksFartrc%3D (Pubitemid 38638124)
29. JG Krueger A Bowcock 2005 Psoriasis pathophysiology: current concepts of pathogenesis Ann Rheum Dis 64 Suppl 2 ii30 ii36 15708932 10.1136/ard.2004.031120 1:CAS:528:DC%2BD2MXisVOrtbw%3D (Pubitemid 40288517)
30. EM Esparza RH Arch 2005 Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation J Immunol 174 7869 7874 15944292 1:CAS:528:DC%2BD2MXkvVOmu7o%3D